EZZ Life Science Holdings Ltd. (AU:EZZ)
ASX:EZZ
Want to see AU:EZZ full AI Analyst Report?
EZZ Stock Chart & Stats
AU$1.45
-AU$0.25(-8.71%)
At close: 4:00 PM EST
AU$1.45
-AU$0.25(-8.71%)
Day’s Range― - ―
52-Week RangeAU$0.50 - AU$3.38
Previous CloseN/A
Volume93.44K
Average Volume (3M)49.70K
Market Cap
AU$23.76M
Enterprise ValueAU$11.11M
Total Cash (Recent Filing)AU$13.47M
Total Debt (Recent Filing)AU$123.86K
Price to Earnings (P/E)8.2
Beta1.24
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.81%
Share Statistics
EPS (TTM)0.06
Shares Outstanding47,043,200
10 Day Avg. Volume67,551
30 Day Avg. Volume49,696
Financial Highlights & Ratios
PEG Ratio-2.57
Price to Book (P/B)3.85
Price to Sales (P/S)1.62
P/FCF Ratio26.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross And Net MarginsSustained gross margins above 70% and a mid-single-digit to low-double-digit net margin indicate durable pricing power and cost efficiency in core products. This margin profile supports reinvestment, resilience to input-cost shocks, and capacity to fund dividends or strategic initiatives over months.
Very Low Leverage And Solid Equity BaseA very low debt-to-equity ratio and strong equity financing reduce solvency risk and preserve financial flexibility. This structural balance-sheet strength supports funding of working capital, opportunistic M&A, and dividend continuation without reliance on volatile external debt markets.
Consumer Health Focus With Cross-border ChannelsPositioning in vitamins/supplements and established cross-border e-commerce distribution into Asian markets taps secular wellness demand and expanding digital channels. These structural industry trends broaden the addressable market and reduce dependence on a single retail channel over the medium term.
Bears Say
Recent Revenue DeclineA double-digit revenue decline suggests weakening end-market demand or competitive pressure and undermines growth prospects. Over months this can compress operating leverage, limit ability to scale, and put pressure on long-term investment plans and top-line recovery unless new channels or products restore traction.
Weak Cash ConversionOperating cash flow converting less than reported income and recent declines in free cash flow growth signal difficulty turning profits into usable cash. This constrains reinvestment, weakens dividend durability, and increases reliance on the balance sheet to fund working capital or strategic initiatives over the medium term.
Small Scale And Volatile EarningsVery limited staffing and steep EPS contraction indicate constrained operating scale and execution risk. Small organizational scale can limit marketing, distribution expansion, and product development capacity, making consistent revenue recovery and durable margin maintenance more challenging over several months.
EZZ Life Science Holdings Ltd. News
EZZ FAQ
What was EZZ Life Science Holdings Ltd.’s price range in the past 12 months?
EZZ Life Science Holdings Ltd. lowest share price was AU$0.50 and its highest was AU$3.38 in the past 12 months.
What is EZZ Life Science Holdings Ltd.’s market cap?
EZZ Life Science Holdings Ltd.’s market cap is AU$23.76M.
When is EZZ Life Science Holdings Ltd.’s upcoming earnings report date?
EZZ Life Science Holdings Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 74 days.
How were EZZ Life Science Holdings Ltd.’s earnings last quarter?
EZZ Life Science Holdings Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.014.
Is EZZ Life Science Holdings Ltd. overvalued?
According to Wall Street analysts EZZ Life Science Holdings Ltd.’s price is currently Overvalued.
Does EZZ Life Science Holdings Ltd. pay dividends?
EZZ Life Science Holdings Ltd. pays a Semiannually dividend of AU$0.02 which represents an annual dividend yield of 2.81%. See more information on EZZ Life Science Holdings Ltd. dividends here
What is EZZ Life Science Holdings Ltd.’s EPS estimate?
EZZ Life Science Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EZZ Life Science Holdings Ltd. have?
EZZ Life Science Holdings Ltd. has 47,043,200 shares outstanding.
What happened to EZZ Life Science Holdings Ltd.’s price movement after its last earnings report?
EZZ Life Science Holdings Ltd. reported an EPS of -AU$0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.326%.
Which hedge fund is a major shareholder of EZZ Life Science Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:EZZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EZZ Life Science Holdings Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
AU:EZZ Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.51%
12-Months-Change
Fundamentals
Return on Equity
10.35%
Trailing 12-Months
Asset Growth
9.62%
Trailing 12-Months
Company Description
EZZ Life Science Holdings Ltd.
EZZ Life Science Holdings Limited, an Australian company, specializes in offering a range of skincare and consumer health products, with its market presence extending across Australia, New Zealand, Mainland China, and other international territories. The company's operations are divided into two distinct segments: 'Brought in Lines' and 'Company Owned products.' EZZ is actively involved in the wholesale supply of its EAORON-branded skincare portfolio, distributing it to pharmacies, major supermarkets, specialist retailers, and general grocery stores. Furthermore, the company designs, develops, manufactures, and markets a comprehensive selection of consumer health products under its own EZZ brand. This extensive offering includes vitamins, dietary supplements, sports nutrition, weight management and wellbeing solutions, traditional herbal remedies, and paediatric lines. These EZZ-branded items are sold directly to consumers via its e-commerce platforms and various retail stores, notably Tmall Global. Founded in 2015, EZZ Life Science Holdings Limited maintains its corporate headquarters in Silverwater, Australia.
Technical Analysis
Amplia Therapeutics
―
Imugene
―
Alterity Therapeutics
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---